1. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Issue 11 (11th September 2020) Authors: de Castro, Carlos; Grossi, Federico; Weitz, Ilene Ceil; Maciejewski, Jaroslaw; Sharma, Vivek; Roman, Eloy; Brodsky, Robert A.; Tan, Lisa; Di Casoli, Carl; El Mehdi, Delphine; Deschatelets, Pascal; Francois, Cedric Journal: American journal of hematology Issue: Volume 95:Issue 11(2020:Nov.) Page Start: 1334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Issue 9 (September 2022) Authors: de Latour, Régis Peffault; Szer, Jeff; Weitz, Ilene C; Röth, Alexander; Höchsmann, Britta; Panse, Jens; Usuki, Kensuke; Griffin, Morag; Kiladjian, Jean-Jacques; de Castro, Carlos M; Nishimori, Hisakazu; Ajayi, Temitayo; Al-Adhami, Mohammed; Deschatelets, Pascal; Francois, Cedric; Grossi, Federico... Journal: Lancet Issue: Volume 9:Issue 9(2022) Page Start: e648 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗